Table 2.

Prevention of hind paw inflammation by combined intravenous and subcutaneous administration of clodronate liposomes

		Clodronate
Characteristic	Control	Intraperitoneal injection only*	Intraperitoneal and subcutaneous injection*
Paws, no.	32	48	12
Median onset, d, 95% CIs	42 ± 8	40 ± 6	ND
Affected at 8 wk†, %	66	66	0§
Severe inflammation‡, %	43	40	0∥

ND indicates no disease.

^*Injection intraperitoneally twice and subcutaneously once weekly for 4 weeks. Controls were injected intraperitoneally or subcutaneously, or both, with PBS liposomes

^†End of observation period

^‡Grade 3 or 4 (grades: 0, no inflammation; 1, slight restricted redness; 2, redness and swelling; 3, redness and massive swelling or affecting large areas; 4, redness and massive swelling or affecting large areas plus extended oozing or necrosis)

^§P < .001; Kaplan-Meier analysis with post hoc log rank test

^∥P < .01; χ² analysis and Fisher exact test